Form 4 for LRCX Lam Research
Accepted 2025-02-06 00:00:00 ET · period of report 2025-02-04 · accession 0000707549-25-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-06 | 2025-02-04 | LRCX | Correia Christina | CAO, CVP | M - OptEx | $0.00 | +2,881 | 45.8K | +7% | $0 |
| D | 2025-02-06 | 2025-02-04 | LRCX | Correia Christina | CAO, CVP | M - OptEx | $0.00 | -5,060 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-04 | M | A | 2,881 | $0.00 | 45,761 | D | — | — | (F1) On 03/01/2022, the Reporting Person received a target grant of 5,060 Market-based Performance Restricted Stock Units vesting between 0% and 150% on 03/01/2025. The vesting of this award is based on the total return stock price performance of Lam Research shares (assuming reinvestment of dividends) relative to the market price performance of the PHLX Semiconductor Sector Total Return Index, comparing the 50-trading day trailing average closing price over the performance period from 02/01/2022 through 01/31/2025 (F2) The amount reported includes shares subject to unvested restricted stock units. |
| 2 | Derivative | Market-based Performance Restricted Stock Unit | 2025-02-04 | M | D | 5,060 | $0.00 | 0 | D | $0.00 · — to — | 5,060 Common Stock | (F3) The Market-based performance restricted stock units will vest between 0% and 150% on 03/01/2025. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Total Return Index Total Shareholder Return during the performance period of 02/01/2022 through 01/31/2025. |